July 2025 in “Journal of Dermatology Research and Therapy” Verteporfin may improve hair regrowth and reduce scarring after hair transplants.
60 citations
,
June 1997 in “Drugs & Aging” Mitoxantrone with a corticosteroid helps manage symptoms for some advanced prostate cancer patients but doesn't extend life.
February 2017 in “Cancer Research” Topical calcitriol appears safe and may reduce hair loss during chemotherapy.
November 2008 in “Cancer Prevention Research” Chemoprevention can significantly lower cancer risks and needs more research and collaboration.
22 citations
,
November 2002 in “Clinical journal of oncology nursing” Arsenic trioxide effectively treats relapsed acute promyelocytic leukemia with manageable side effects.
1 citations
,
July 2014 in “International Journal of Dermatology” A cancer patient developed a type of hair loss after starting a cancer drug called vandetanib.
4 citations
,
February 2025 in “Pharmaceuticals” Voglibose may help treat skin hyperpigmentation safely.
5 citations
,
June 2024 in “Pharmacological Research” FOL-026 peptide may help hair growth and cardiovascular health by improving blood flow and cell functions.
45 citations
,
October 2018 in “JCI Insight” Entospletinib effectively prevents eye and skin GVHD in mice.
August 2024 in “Asian Journal of Research in Chemistry” Repurposing existing drugs can improve cancer treatment but faces challenges.
28 citations
,
September 2014 in “Journal of Veterinary Internal Medicine” VDC-1101 shows potential as a treatment for canine cutaneous T-cell lymphoma.
May 2018 in “Journal of Clinical Oncology” The treatment is safe and shows promise for metastatic breast cancer.
52 citations
,
May 1993 in “Southern Medical Journal” Imuvert can prevent some chemotherapy-induced hair loss.
1 citations
,
November 2014 in “Thérapie” Potassium channel activators like nicotinamide and minoxidil might help treat solid tumors.
May 2019 in “Journal of clinical oncology” Topical calcitriol was safe and well-tolerated for potential hair loss prevention in chemotherapy patients.
April 2010 in “Nature Reviews Urology”
37 citations
,
September 2018 in “The Journal of Clinical Endocrinology and Metabolism” Intravaginal testosterone cream improves sexual satisfaction and reduces vaginal discomfort in postmenopausal women on breast cancer treatment without affecting hormone levels.
37 citations
,
October 2017 in “Clinical and Experimental Dermatology” Oral tofacitinib shows promise in treating atopic dermatitis and alopecia areata, but only slight improvement in vitiligo.
9 citations
,
April 2024 in “The Oncologist” Sacituzumab govitecan improves quality of life and symptoms in breast cancer patients, except for causing more diarrhea.
December 2025 in “Scientific Reports” Valproic acid helps hair follicle stem cells survive better in low oxygen and glucose conditions.
34 citations
,
October 2021 in “Scientific Reports” Nobiletin-loaded vesicles effectively treat skin cancer by restoring normal miRNA and antioxidant levels.
59 citations
,
March 2003 in “The Lancet” Imatinib can repigment grey hair, while SU11428 can cause temporary hair depigmentation.
6 citations
,
November 2023 in “Clinical Pharmacokinetics” Ritlecitinib shows promise as a versatile treatment for various autoimmune and inflammatory diseases.
March 2026 in “Pharmaceutics” Plant-derived nanovesicles show promise in cancer treatment but need standardized preparation.
March 2023 in “Oxford University Press eBooks”
27 citations
,
September 2017 in “Archives of Dermatological Research” Topical tofacitinib may grow hair better than minoxidil by increasing VEGF and reducing inflammation.
20 citations
,
May 2023 in “Cancer Nanotechnology” The new drug delivery system effectively targets lung cancer cells.
October 2025 in “Actualización en Medicina de Familia” New drugs face challenges due to limited evidence, and safety updates are advised for some existing medications.
400 citations
,
October 1995 in “Journal of clinical oncology” Docetaxel is effective against various cancers but mainly causes neutropenia.
September 2024 in “Annals of Medicine and Surgery” Ritlecitinib is the first FDA-approved pill for treating significant hair loss in alopecia areata patients aged 12 and up.